May 13th 2025
The proposed $700 million, 700,000-square-foot space will support the companies’ future joint portfolio of next-generation obesity medicines.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Six Sigma and the Path to Quality
October 2nd 2017Lawrence Yu, deputy director of the Office of Pharmaceutical Quality (OPQ), Center for Drug Evaluation and Research (CDER), and his FDA colleague, Michael Kopcha highlight the importance of Six Sigma approaches to continuous improvement in the pharmaceutical industry.
Gerresheimer Presents Gx Elite Vials at CPhI Worldwide
September 27th 2017The Gx Elite vials are the result of comprehensive optimization measures in the conversion process, which have focused on designing out the risk to create product flaws during production including the removal of all glass-to-glass contact beginning with the tubing material all the way through final packaging.